GT Biopharma Inc (GTBP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -2,833 | -28,354 | -22,646 | -30,945 | -776 |
| Income taxes - deferred | N/A | -11,413 | N/A | N/A | N/A |
| Accounts payable and accrued liabilities | N/A | -1,297 | N/A | -1,623 | N/A |
| Other Working Capital | 330 | -920 | -2,558 | -1,848 | -1,303 |
| Other Operating Activity | 35 | 29,070 | 16,311 | 29,200 | -123 |
| Operating Cash Flow | $-2,468 | $-12,914 | $-8,893 | $-5,216 | $-2,202 |
| Cash Flows From Investing Activities | |||||
| Investing Cash Flow | $N/A | $N/A | $N/A | $N/A | $N/A |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | N/A | 5,496 | 1,052 | 1,052 | N/A |
| Common Stock Repurchased | 577 | N/A | N/A | N/A | 616 |
| Dividend Paid | N/A | N/A | -85 | N/A | N/A |
| Other Financing Activity | 4,003 | 10,279 | 6,503 | 5,441 | 0 |
| Financing Cash Flow | $4,580 | $15,775 | $7,470 | $6,493 | $616 |
| Beginning Cash Position | 6,905 | 4,044 | 4,044 | 4,044 | 4,044 |
| End Cash Position | 9,017 | 6,905 | 2,621 | 5,321 | 2,458 |
| Net Cash Flow | $2,112 | $2,861 | $-1,423 | $1,277 | $-1,586 |
| Free Cash Flow | |||||
| Operating Cash Flow | -2,468 | -12,914 | -8,893 | -5,216 | -2,202 |
| Free Cash Flow | -2,468 | -12,914 | -8,893 | -5,216 | -2,202 |